Article
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
The New England journal of medicine - 16 Sept 2010
Verstovsek Srdan, Kantarjian Hagop, Mesa Ruben A, Pardanani Animesh D, Cortes-Franco Jorge, Thomas Deborah A, Estrov Zeev, Fridman Jordan S, Bradley Edward C, Erickson-Viitanen Susan, Vaddi Kris, Levy Richard, Tefferi Ayalew
Abstract excerpt
BACKGROUND: Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival. About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiology of the disease. INCB018424 is a potent and selective Janus kinase 1 (JAK1) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.